APVO210 is a humanized, targeted cytokine therapeutic under development for the treatment of ulcerative colitis and has potential utility in multiple autoimmune diseases. APVO210 was engineered using our bispecific ADAPTIRTM technology platform to deliver a modified form of the immunosuppressive cytokine IL-10 to antigen-presenting cells by targeting CD86.
APVO210 is designed to suppress T-cell responses through inhibition of antigen presentation.
Antigen-presenting cells play a central role in the generation and regulation of immunity. APVO210 has been engineered to produce superior and specific IL-10-induced inhibition of antigen presentation in a format that may provide manufacturing advantages and may extend the serum half-life relative to wild-type cytokines.
In addition to ulcerative colitis, APVO210 has potential applications in autoimmune and inflammatory diseases such as Crohn’s disease, rheumatoid arthritis and transplant rejection.